Jonathan Chang
Stock Analyst at Leerink Partners
(0.63)
# 4,118
Out of 5,124 analysts
81
Total ratings
30.67%
Success rate
-19.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Upgrades: Outperform | $3 → $13 | $8.45 | +53.85% | 11 | Oct 20, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $18.20 | +312.09% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $33.10 | -18.43% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $32.76 | +125.89% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $20.37 | -46.00% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $14.29 | +256.89% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $7.35 | +920.41% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $6.57 | +661.04% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $79.85 | -62.43% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.70 | +605.88% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $29.30 | +1,094.54% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $9.60 | +170.83% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $9.54 | +193.50% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $14.06 | +276.96% | 7 | Aug 5, 2021 |
Replimune Group
Oct 20, 2025
Upgrades: Outperform
Price Target: $3 → $13
Current: $8.45
Upside: +53.85%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $18.20
Upside: +312.09%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $33.10
Upside: -18.43%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $32.76
Upside: +125.89%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $20.37
Upside: -46.00%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $14.29
Upside: +256.89%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $7.35
Upside: +920.41%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $6.57
Upside: +661.04%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $79.85
Upside: -62.43%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.70
Upside: +605.88%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $29.30
Upside: +1,094.54%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $9.60
Upside: +170.83%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $9.54
Upside: +193.50%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $14.06
Upside: +276.96%